IL270365A - - Google Patents

Info

Publication number
IL270365A
IL270365A IL27036519A IL27036519A IL270365A IL 270365 A IL270365 A IL 270365A IL 27036519 A IL27036519 A IL 27036519A IL 27036519 A IL27036519 A IL 27036519A IL 270365 A IL270365 A IL 270365A
Authority
IL
Israel
Application number
IL27036519A
Other languages
English (en)
Other versions
IL270365B1 (en
IL270365B2 (en
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of IL270365A publication Critical patent/IL270365A/en
Publication of IL270365B1 publication Critical patent/IL270365B1/en
Publication of IL270365B2 publication Critical patent/IL270365B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/99—Serum-free medium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/21—Chemokines, e.g. MIP-1, MIP-2, RANTES, MCP, PF-4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2301—Interleukin-1 (IL-1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2304—Interleukin-4 (IL-4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2309—Interleukin-9 (IL-9)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2312—Interleukin-12 (IL-12)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2318—Interleukin-18 (IL-18)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2321—Interleukin-21 (IL-21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2333—Interleukin-33 (IL-33)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL270365A 2017-05-03 2018-05-03 Expansion of gamma delta t cells, compositions, and methods of use thereof IL270365B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1707048.3A GB201707048D0 (en) 2017-05-03 2017-05-03 Expansion of gamma delta cells, compositions, and methods of use thereof
PCT/EP2018/061413 WO2018202808A2 (en) 2017-05-03 2018-05-03 Expansion of gamma delta t cells, compositions, and methods of use thereof

Publications (3)

Publication Number Publication Date
IL270365A true IL270365A (cg-RX-API-DMAC7.html) 2019-12-31
IL270365B1 IL270365B1 (en) 2024-06-01
IL270365B2 IL270365B2 (en) 2024-10-01

Family

ID=59010925

Family Applications (3)

Application Number Title Priority Date Filing Date
IL270365A IL270365B2 (en) 2017-05-03 2018-05-03 Expansion of gamma delta t cells, compositions, and methods of use thereof
IL319114A IL319114A (en) 2017-05-03 2018-05-03 Expansion of gamma delta T cells, compositions and methods for use thereof
IL312633A IL312633B2 (en) 2017-05-03 2018-05-03 Expansion of gamma delta t cells, compositions, and methods of use thereof

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL319114A IL319114A (en) 2017-05-03 2018-05-03 Expansion of gamma delta T cells, compositions and methods for use thereof
IL312633A IL312633B2 (en) 2017-05-03 2018-05-03 Expansion of gamma delta t cells, compositions, and methods of use thereof

Country Status (14)

Country Link
US (3) US11655453B2 (cg-RX-API-DMAC7.html)
EP (1) EP3619298A2 (cg-RX-API-DMAC7.html)
JP (3) JP2020518289A (cg-RX-API-DMAC7.html)
KR (2) KR20250080907A (cg-RX-API-DMAC7.html)
CN (1) CN110914410A (cg-RX-API-DMAC7.html)
AU (2) AU2018262698B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019023076A2 (cg-RX-API-DMAC7.html)
CA (1) CA3062386A1 (cg-RX-API-DMAC7.html)
EA (1) EA201992610A1 (cg-RX-API-DMAC7.html)
GB (1) GB201707048D0 (cg-RX-API-DMAC7.html)
IL (3) IL270365B2 (cg-RX-API-DMAC7.html)
MX (2) MX2019013001A (cg-RX-API-DMAC7.html)
PH (1) PH12019502485A1 (cg-RX-API-DMAC7.html)
WO (1) WO2018202808A2 (cg-RX-API-DMAC7.html)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1814580B1 (en) 2004-11-24 2016-08-10 Fred Hutchinson Cancer Research Center Methods of using il-21 for adoptive immunotherapy and identification of tumor antigens
GB201707048D0 (en) 2017-05-03 2017-06-14 King S College London Expansion of gamma delta cells, compositions, and methods of use thereof
GB201804701D0 (en) 2018-03-23 2018-05-09 Gammadelta Therapeutics Ltd Lymphocytes expressing heterologous targeting constructs
GB201818243D0 (en) * 2018-11-08 2018-12-26 Gammadelta Therapeutics Ltd Methods for isolating and expanding cells
KR20210111746A (ko) 2018-11-08 2021-09-13 감마델타 테라퓨틱스 리미티드 세포를 단리 및 증식하는 방법
CN109517793B (zh) * 2018-11-30 2022-05-10 广州长峰生物技术有限公司 一种NK细胞和γδT细胞共培养的建立方法
GB201909144D0 (en) * 2019-06-25 2019-08-07 Autolus Ltd Culture medium
LT4051710T (lt) 2019-10-31 2026-03-10 Incyte Corporation Priešnavikinė kompleksinė terapija, apimanti anti-cd19 antikūną ir gama delta ląsteles
IL293459A (en) * 2019-12-03 2022-07-01 Adicet Bio Inc Methods for expanding γδ t-cell populations with multivalent agents and compositions thereof
US20210290674A1 (en) * 2020-03-20 2021-09-23 GammaDelta Therapeutics Ltd. Methods for treating myeloid malignancies
WO2021186137A1 (en) 2020-03-20 2021-09-23 GammaDelta Therapeutics Limited V delta1+ t cells for the treatment of myeloid malignancies
GB202006989D0 (en) 2020-05-12 2020-06-24 Gammadelta Therapeutics Ltd Methods for isolating gamma delta t cells
GB202013962D0 (en) * 2020-09-04 2020-10-21 Gammadelta Therapeutics Ltd Immunotherapy composition
CN113234675A (zh) * 2021-03-31 2021-08-10 广西医科大学 一种γδT细胞以及采用体外制备γδT细胞的方法
GB202105113D0 (en) * 2021-04-09 2021-05-26 Gammadelta Therapeutics Ltd Novel method
WO2022221439A1 (en) * 2021-04-14 2022-10-20 The Trustees Of The University Of Pennsylvania Methods to determine treatment efficacy with gamma-delta t cells
AU2022258567B2 (en) * 2021-04-16 2026-06-18 Acepodia Biotechnologies Ltd. Novel compositions enriched in gamma delta t cells, methods of preparation, and uses thereof
WO2023069322A1 (en) * 2021-10-20 2023-04-27 University Of Pittsburgh – Of The Commonwealth System Of Higher Education Methods and materials for expanding tumor infiltrating gamma-delta t cells
JP2025504363A (ja) * 2022-01-05 2025-02-12 インヒブルクス バイオサイエンシズ インコーポレイテッド γδT細胞結合ポリペプチド及びその使用
EP4680729A1 (en) * 2023-03-17 2026-01-21 Legend Biotech Ireland Limited Methods of culturing v delta 1 t cells
WO2024209429A1 (en) 2023-04-07 2024-10-10 Takeda Pharmaceutical Company Limited T cells for use in treating relapsed or refractory acute myeloid leukemia
WO2025017531A1 (en) 2023-07-20 2025-01-23 Takeda Pharmaceutical Company Limited Grid-free methods for making gamma delta t cells
JP2026526851A (ja) * 2023-07-26 2026-08-10 ヤンセン バイオテツク,インコーポレーテツド 細胞増殖のための材料及び方法
WO2026096605A1 (en) * 2024-10-31 2026-05-07 Pointloma Biosciences, Inc. Methods for activation and expansion of gamma delta t cells
WO2026110042A1 (en) * 2024-11-19 2026-05-28 King's College London Methods of expansion of skin vdelta1+ gammadelta t cells and use of same
KR20260090785A (ko) * 2024-12-09 2026-06-17 한국과학기술원 체내 지속성 및 항종양 효과가 향상된 세포치료제, 및 이의 제조방법
WO2026133284A1 (en) 2024-12-19 2026-06-25 Takeda Pharmaceutical Company Limited Methods of expanding and production of gammadelta t cells
EP4779306A1 (en) * 2025-01-17 2026-07-22 HUB Organoids IP B.V. Co-cultures of organoids, stromal cells and immune cells

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6028176A (en) 1996-07-19 2000-02-22 Bayer Corporation High-affinity interleukin-4 muteins
NZ511760A (en) 1998-11-04 2003-10-31 Hemosol Inc Methods for the production of TcR gamma delta T cells
EP1777294A1 (en) 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
US20070122413A1 (en) 2005-11-28 2007-05-31 Sivakumar Pallavur V Il-21 antagonists
WO2012088446A1 (en) 2010-12-22 2012-06-28 Board Of Trustees Of The Leland Stanford Junior University Superagonists and antagonists of interleukin-2
EP2710123B1 (en) 2011-05-19 2017-07-12 Instituto de Medicina Molecular Cell line of lymphocytes comprising gamma-delta t cells, composition and production method thereof
ES2539845B1 (es) 2013-08-05 2016-04-13 Universidad De Alicante Procedimiento y síntesis de monolitos de carbón activo a partir de cascarilla de cacao
US9907820B2 (en) * 2013-10-25 2018-03-06 Board Of Regents, The University Of Texas System Polyclonal gamma delta T cells for immunotherapy
UA123821C2 (uk) * 2014-06-11 2021-06-09 Полібіосепт Гмбх Композиція для експансії лімфоцитів in vitro
GB201506423D0 (en) 2015-04-15 2015-05-27 Tc Biopharm Ltd Gamma delta T cells and uses thereof
RU2756247C2 (ru) * 2014-11-17 2021-09-28 Эдисет Био, Инк. Генетически модифицированные гамма дельта т-клетки
US11150242B2 (en) * 2015-04-10 2021-10-19 President And Fellows Of Harvard College Immune cell trapping devices and methods for making and using the same
JP6799895B2 (ja) * 2015-06-09 2020-12-16 リンファクト−リンフォサイト アクティベイション テクノロジーズ エス.エー. TCRγδ+T細胞の生産方法
US10829735B2 (en) 2015-07-21 2020-11-10 The Trustees Of The University Of Pennsylvania Methods for improving the efficacy and expansion of immune cells
CN108473958A (zh) 2015-10-30 2018-08-31 癌症研究技术有限公司 非造血组织驻留γδT细胞的扩增及这些细胞的用途
GB201707048D0 (en) 2017-05-03 2017-06-14 King S College London Expansion of gamma delta cells, compositions, and methods of use thereof

Also Published As

Publication number Publication date
PH12019502485A1 (en) 2021-01-04
AU2018262698B2 (en) 2025-07-03
IL270365B1 (en) 2024-06-01
MX2019013001A (es) 2021-01-20
JP7698672B2 (ja) 2025-06-25
WO2018202808A2 (en) 2018-11-08
AU2018262698A1 (en) 2019-12-12
EA201992610A1 (ru) 2020-04-23
CA3062386A1 (en) 2018-11-08
IL270365B2 (en) 2024-10-01
JP2025134795A (ja) 2025-09-17
US20210087528A1 (en) 2021-03-25
AU2025230679A1 (en) 2025-10-02
CN110914410A (zh) 2020-03-24
BR112019023076A2 (pt) 2020-06-09
IL312633B2 (en) 2025-08-01
GB201707048D0 (en) 2017-06-14
MX2024004897A (es) 2024-05-07
US20230242878A1 (en) 2023-08-03
EP3619298A2 (en) 2020-03-11
WO2018202808A3 (en) 2019-01-03
KR20250080907A (ko) 2025-06-05
WO2018202808A9 (en) 2019-03-07
IL312633A (en) 2024-07-01
US20260174861A1 (en) 2026-06-25
US12458698B2 (en) 2025-11-04
KR20200024770A (ko) 2020-03-09
JP2020518289A (ja) 2020-06-25
KR102812405B1 (ko) 2025-05-23
US11655453B2 (en) 2023-05-23
JP2023058687A (ja) 2023-04-25
IL312633B1 (en) 2025-04-01
IL319114A (en) 2025-04-01

Similar Documents

Publication Publication Date Title
BR122021000189A2 (cg-RX-API-DMAC7.html)
BR112019008823A2 (cg-RX-API-DMAC7.html)
BR112020006084A8 (cg-RX-API-DMAC7.html)
BR112019025875B1 (pt) Sistema de cilindro com estrutura de ocupação de movimento relativo
BR112020011860B1 (pt) Dispositivo cirúrgico para cortar uma lente dentro de um saco capsular de um olho
BR112020006283B1 (pt) Placa refinadora, e, refinador para tratamento mecânico de material orgânico/celulósico
BR112020008714B1 (pt) Uso de medicamentos serotoninérgicos para tratar trombocitopenia induzida por vírus
BR112020006992B1 (pt) Dispositivo de recolhimento e método para o recolhimento de uma embarcação
BR112020003314B1 (pt) Sistema terapêutico transdérmico para administração transdérmica de um agente ativo, seu método de fabricação, usos de emulsificante, e método para estabilizar uma mistura de revestimento bifásica
BR112020003112B1 (pt) Método de garantir a viabilidade de uma máquina para uma tarefa agendada
BR112020002577B1 (pt) Método de melhoria de rendimento de centrifugação dupla para purificação de óleo nutritivo
BR112019016885B1 (pt) Remodelagem de imagem integrada e codificação de vídeo
BR112019027876B1 (pt) Método de codificação para uma comunicação sem fio, codificador, método de decodificação, decodificador, aparelho de comunicação, meio de armazenagem legível por computador, e sistema de comunicações
BR112020001354B1 (pt) Método, em uma primeira estação base, para suportar posicionamento de um dispositivo móvel e primeira estação base para suportar posicionamento de um dispositivo móvel
BR112019026818B1 (pt) Método de codificação, método de decodificação, aparelho, aparelho de comunicações, terminal, estação base e mídia legível por computador
BR102018011961B1 (pt) Sistemas, métodos e meio não transitório legível por computador para analisar cores a partir de uma plataforma de mídia social
BR112019024244B1 (pt) Processos de fermentação de metano de alta produtividade
BR112019023944B1 (pt) Combinação farmacêutica para o tratamento de um câncer
BR112019021396B1 (pt) Processo para fabricação de pululano
BR102018003507B1 (pt) Sistema de isolamento de tensão de tambor de guincho
BR112019016182B1 (pt) Método para diagnosticar risco de revisão relacionado a implante
BR112019014127B1 (pt) Composição farmacêutica para tratamento de tumores
BR112019017156B1 (pt) Dispositivo, sistema e método de gerenciamento de recepção de pedido, e, meio de armazenamento legível por computador
BR112019014017B1 (pt) Dispositivo de medição da quantidade de oxigênio presente em um gás, e, módulo de separação de ar
BR112020009459B1 (pt) Método para indicar informações de domínio de frequência do conjunto de recursos de controle comum de informações mínimas remanescentes do sistema